Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06848530 · ClinicalTrials.gov registry record · NA

Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders

A NA study of Movement Disorders, sponsored by University of Pennsylvania.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06848530: Recruiting NA study of Movement Disorders, sponsored by University of Pennsylvania.

NCT06848530 is a NA study of Movement Disorders that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 1,064-participant average among 26 other Movement Disorders trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06848530, a NA study of Movement Disorders, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as Parkinson's disease, essential tremor, dystonia, or ataxia). These brain structures are involved in movement disorders. This study attempts to better understand the brain electrical activity associated with these disorders, both in patients with and without deep brain stimulation (DBS). Recordings are made from the scalp with a noninvasive electrode and/or through the DBS stimulator if the participant has a stimulator model that is able to sense brain activity. These recordings are analyzed along with measures of movement disorder symptoms to identify brain signal signatures of symptoms.

Primary Outcome

Spatiotemporal patterns of brain neural activity (neural signal biomarkers / neurophysiologic signatures) associated with movement disorders symptoms.

Conditions Studied

Interventions

  • OTHER Prescribed Medications
  • OTHER Deep brain stimulation adjustment

Study Locations (1)

Pennsylvania

  • Pennsylvania Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-12-10
Est. Completion 2030-04
Phase NA
University of Pennsylvania

1,423 total trials

What NCT06848530 shows while recruiting

NCT06848530 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,064-participant average among 26 other Movement Disorders trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Movement Disorders appearing as the primary indexed condition, and to 2 interventions - of which Prescribed Medications is the first listed.

NCT06848530 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06848530 about?

NCT06848530 is a clinical study titled "Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders". The research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as Parkinson's disease, essential tremor, dystonia, or ataxia). These brain structures are involved in movement dis...

What is the current status of trial NCT06848530?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-12-10. Estimated completion is 2030-04.

What conditions does trial NCT06848530 study?

This clinical trial studies the following conditions: Movement Disorders.

What interventions are being tested in trial NCT06848530?

The interventions under investigation include: Prescribed Medications (OTHER), Deep brain stimulation adjustment (OTHER).

Who is sponsoring clinical trial NCT06848530?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06848530 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Movement Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06848530's enrollment target sits among peer trials

100 13th of 26 higher than 11 of 26 other Movement Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Movement Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06848530, the US trial registry maintained by the National Library of Medicine. NCT06848530 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.